Indaptus Therapeutics’ (INDP) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Indaptus Therapeutics (NASDAQ:INDP) in a research report released on Wednesday morning, Benzinga reports. HC Wainwright currently has a $12.00 target price on the stock.

Indaptus Therapeutics Price Performance

NASDAQ INDP opened at $1.43 on Wednesday. Indaptus Therapeutics has a one year low of $1.03 and a one year high of $3.25. The business has a 50 day simple moving average of $1.45 and a 200 day simple moving average of $1.99. The stock has a market capitalization of $12.21 million, a P/E ratio of -0.80 and a beta of 1.46.

Indaptus Therapeutics (NASDAQ:INDP) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.07. Equities analysts expect that Indaptus Therapeutics will post -1.72 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Indaptus Therapeutics stock. Virtu Financial LLC purchased a new stake in Indaptus Therapeutics, Inc. (NASDAQ:INDP) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 14,232 shares of the company’s stock, valued at approximately $32,000. Virtu Financial LLC owned 0.17% of Indaptus Therapeutics at the end of the most recent quarter. 7.06% of the stock is owned by institutional investors.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.